SEYMOUR Len バーミンガム大学医学部, がん研究センター, 助教授
KERR David J バーミンガム大学医学部, がん研究センター, 所長/教授
OLLIFF Simon バーミンガム大学医学部, クィーンエリザベスII病院, 講師
KONNO Toshimitsu Kumamoto University Hospital, Assistant Professor, 医学部附属病院, 講師 (60117348)
SEYMOUR Len W. The University of Birmingham, CRC Institute for Cancer Studies, Associate Profes
OLLIFF Simon P. The University of Birmingham, Queen Elizabeth Hospital, Assistant Professor
KERR David J. The University of Birmingham, CRC Institute for Cancer Studies, Director/Profess
|Budget Amount *help
¥1,800,000 (Direct Cost : ¥1,800,000)
Fiscal Year 1998 : ¥600,000 (Direct Cost : ¥600,000)
Fiscal Year 1997 : ¥600,000 (Direct Cost : ¥600,000)
Fiscal Year 1996 : ¥600,000 (Direct Cost : ¥600,000)
(1)To disseminate the state of the art for the treatment of primary cancer, the arterialinlection of SMANCS/Lipiodol with the hepatic or tumor feeding artery was performed at Queen Elizabeth II Hospital of the University of Birmingham, U.K.This method was new in Europe.
(2)We could confirm that this method, developed in Japan, is similarly effective inpatients in U.K.
(3)The understanding of the new concept for cancer chemotherapy is now established among oncologists in Birmingham, U.K.Namely, the amount of drug needs to result in regression of tumor should be based on the tumor size but not maximum tolerable dose as practiced in old concept. That is, dose regimen is proportional to the tumor size, which is also parallel to the response rate, but not body weight or surface area of the patients as in old concept. The rationale behinds this theory is that arterial administration of oily formulation is most selectively targeted to the tumor (> 1000-fold in tumor/blood concentration), but th
is delivery method drug distribution was found of very little to elsewhere innormal tissues or organs. Thus, excessive amount of drug dosage is not needed in our system, which could damage normal tissues or organs.
(4)These clinical data from Queen Elizabeth II Hospital of the University of Biririgham were reported recently in two journals, and also in Joint Meeting of NCl (USA) EORTC (Europe) in June, 1998, Amsterdam.
(5)Utilizing this most effective tumor delivery system using lipiodol via tumor feeding artery, recombinant DNA of interteron-gamma (IFN-gamma)-poly L-lysine complex was injected into rabbit bearing VX-2 carcinoma in the liver. The result showed that gene was delivery to the tumor selectively, which expressing beta-galactosidase gene, but expression of IFN-gamma was very little or none. This indicates that enhanced and sustained gene expression is the key issue at this point for gene therapy, and yet premature.
(6)After obtaining a convincing result for the treatment of the primary liver cancer, we decided to approach our final goal ; that is, the control of colon cancer metastasis to the liver. The first choice of the treatment of colon cancer is surgical resection, however, about half of the patients undergo surgical removal of tumor develops liver metastasis. Our protocol is to inject SMANCS/Lipiodol (1-2 ml) into the portal vein upon surgery (laporatomy) because it is considered that colon tumor shedding or dissemination occurs during the surgical resection. Our experimental data using rabbit model showed that the incidence of cancer metastasis is reduced to less than 1 % of control without portal SMANCS treatment by SMANCS/Lipiodol via the portal vein. The collaborative study will be initiated within six months it we could find a sponsor. Less